Reneo Pharmaceuticals Inc. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים RPHM

Reneo Pharmaceuticals (RPHM) relies on outsourcing the production of molecules for myopathies. The company has prioritized the implementation of ESG standards in biopharmaceuticals and strict adherence to bioethics. The annual EPS TTM YoY trend confirms the dynamics of these processes, where -18.60 determines the current status of the parameter. In the long term, the creation of unique orphan drugs will provide the firm with significant pricing power in the market.
Reneo Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (RPHM)

This indicator measures the rate of change in net income per share over a rolling twelve-month period. The calculation is based on comparing current total income with the same interval from the previous year to neutralize seasonality. By analyzing the annual net income per share growth rate (ttm), an investor assesses real operational efficiency. For Reneo Pharmaceuticals (RPHM), this trend reflects the financial consequences of asset restructuring. Current fluctuations on the chart confirm the company's transition to an external licensing strategy for new molecules.